Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL (NCT01722487), a randomized phase 3 study. The primary outcome is PFS (Progression Free Survival).

2. Clinical Question

This is a comparison of assigned treatment groups in a randomized, parallel-group study. The registry lists 136 participants in the ibrutinib arm and 133 in the chlorambucil arm for the primary outcome. The question is about the time until progression or death, rather than only whether progression occurred by one fixed date. That distinction matters because participants can have different lengths of follow-up and the timing of events carries information.

The clinical question is bounded by the population enrolled and the outcome definition used. It concerns treatment-naive older patients with the two listed conditions; it does not directly address other patient groups or other treatment settings. The primary result is an estimate based on the registry's stated outcome and analysis, not a complete account of all possible benefits, harms, or patient experiences. The registry record does not report the full protocol or a detailed explanation of how all outcome assessments were conducted.

3. Trial Design

The registry describes a randomized, multicenter, open-label, Phase 3 study with a parallel-group design. It lists 269 participants overall, including 136 assigned to ibrutinib and 133 assigned to chlorambucil for the primary outcome. The listed primary analysis population is intention to treat. Randomization is intended to make treatment groups comparable at assignment, on average, but the registry entries do not describe the sequence-generation or allocation-concealment procedures.

The study was open label, meaning masking was not used for participants and study personnel according to the registry's masking entry. The primary endpoint was nevertheless assessed by an independent review committee. Independent assessment can reduce reliance on judgments made solely by people who know the assigned treatment, although the registry record does not report the committee's operating procedures or whether its members were masked.

The study start is listed as 2013-03, and primary completion as 2015-05. The primary and listed secondary analyses were conducted when 15 months had elapsed after the last participant was randomized, with a cutoff date of 4 May 2015. The registry reports a median follow-up time of 18 month. The study status is completed. The sponsor is Pharmacyclics LLC.

The comparison involved ibrutinib and chlorambucil. The registry describes both as drugs and gives partial administration descriptions, but the available descriptions are truncated. It does not report the study's original sample-size justification, its full statistical analysis plan, interim analysis procedures, or detailed handling of treatment changes and follow-up. Those omissions limit what can be inferred about planning and implementation beyond the design features explicitly recorded.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Intention to treat

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as PFS (Progression Free Survival), measured over Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month..

Progression-free survival (PFS) is the time until a participant experiences disease progression or dies, according to the endpoint's specified rules. It is a time-to-event outcome: the analysis uses both whether an event occurred and when it occurred. This makes it useful when follow-up duration varies among participants and when the timing of disease worsening is of interest. In general, time-to-event methods can account for participants whose event has not been observed by the analysis cutoff, provided the required censoring information and assumptions are handled appropriately. The registry record does not give enough detail to describe those procedures fully.

The primary objective was to compare ibrutinib with chlorambucil using PFS assessed by an independent review committee. Progression was defined according to the 2008 IWCLL guidelines. The listed criteria include increases in lymphadenopathy, hepatomegaly, splenomegaly, or blood lymphocytes, as well as decreases in platelet counts or hemoglobin attributed to chronic lymphocytic leukemia. The registry specifies thresholds for those changes, including an increase of at least 50% for the listed Group A measures and a hemoglobin decrease of more than 2 g/dL for the listed Group B criterion.

A median PFS is the time by which half of the analyzed participants have experienced the event, subject to the time-to-event analysis. The registry reports the chlorambucil median as 18.9 months, with a 95% confidence interval from 14.1 to 22.0 months. A median for ibrutinib is not reported in the registry record. The relative comparison is reported as a hazard ratio; it addresses the event rate over follow-up under the analysis rather than expressing a difference in median times.

7. Results Posted in the Registry

• Chlorambucil: hazard ratio 0.16 (95% CI 0.09–0.28), reported p < 0.001 (as reported in the registry).

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Overall Survival (OS)

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Log Rank); it was not recalculated.
• Result:
  • Chlorambucil: hazard ratio 0.16 (95% CI 0.05–0.56), reported p = 0.001 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically lower for Chlorambucil than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

ORR (Overall Response Rate)

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Chlorambucil: 35.3% (47/133) versus 82.4% (112/136) on control; risk difference -47.0 percentage points (95% CI -57.4 to -36.7), risk ratio 0.43 (0.34–0.55); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Chlorambucil than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Proportion of Sustained Hemoglobin Improvement

• Endpoint type: Binary: the percentage of participants with the event (counts rebuilt from the posted percentages and group sizes).
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Chlorambucil: 20.3% (27/133) versus 45.6% (62/136) on control; risk difference -25.3 percentage points (95% CI -36.1 to -14.5), risk ratio 0.45 (0.30–0.65); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Chlorambucil than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The posted secondary results generally point in the same numerical direction as the primary PFS comparison: the registry reports an overall survival hazard ratio below 1 for the recorded comparison, and the binary outcome percentages are higher in the ibrutinib arm for overall response and sustained hemoglobin improvement. This broad pattern is supportive context, but the endpoints measure different aspects of outcome and should not be treated as interchangeable confirmations of PFS.

Overall survival is a time-to-event endpoint, but neither arm's median is reported in the registry record. Its reported hazard ratio has a 95% confidence interval from 0.05 to 0.56 and p = 0.001. Response and hemoglobin improvement are binary outcomes, with sponsor-reported analyses using methods listed separately from the simple unadjusted recalculations. The numerical pattern alone does not establish that the results are independent of one another, since the same participants and trial context can contribute to multiple outcomes.

The registry lists additional secondary outcomes involving sustained platelet improvement and subsets defined by baseline anemia or thrombocytopenia. Their detailed results are not reported in the registry record. Thus, the full secondary-outcome picture cannot be reconstructed from the listed numerical results.

Secondary outcomes commonly involve multiple comparisons. In general, when many outcomes are tested, the chance of at least one apparently unusual result can increase unless the analysis plan accounts for multiplicity. No multiplicity adjustment or prespecified hierarchy for the secondary tests is reported in the registry record. The p-values for secondary endpoints should therefore carry less weight than a single prespecified primary analysis, particularly when effect estimates and confidence intervals are not posted for the sponsor's binary analyses. They are best understood as additional descriptive evidence rather than as a set of independent definitive tests.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Overall Survival (OS)
• ORR (Overall Response Rate)
• Proportion of Sustained Hemoglobin Improvement
• Proportion of Sustained Hemoglobin Improvement in Subjects With Baseline Anemia
• Proportion of Sustained Platelet Improvement
• Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

9. Statistical Interpretation

10. Statistical Methods Explained

What does a hazard ratio describe?

In general, a hazard is the instantaneous event rate among participants who have not yet experienced the event, considered over follow-up. A hazard ratio compares hazards between groups. It is not a ratio of event counts, a ratio of median survival times, or an absolute risk difference. A hazard ratio of 1 represents equal hazards under the comparison's definition; values on either side of 1 indicate different relative hazards. Interpretation depends on which group is in the numerator and which is the reference group. The registry posts 0.16 for chlorambucil relative to ibrutinib, and the comparison should be read with that recorded ordering rather than silently reoriented.

A hazard ratio also compresses information across event times. In general, it is most straightforward to interpret when the relative hazards are reasonably stable over time. The registry record does not report a test or assessment of that assumption, so no conclusion about it can be made from the posted information. The reported PFS hazard ratio comes from the sponsor's Log Rank analysis. A median PFS is a separate summary of the event-time distribution, not a substitute for the relative hazard estimate.

What does the Log Rank method contribute?

The Log Rank method is a general time-to-event comparison that uses the timing of observed events and the risk sets over follow-up. It evaluates whether the event experience differs between groups across the analysis period. Its test result is expressed in the registry as a p-value, while the associated hazard ratio and confidence interval give an estimate and range of values compatible with the data under the analysis. The registry does not report additional model details, covariate adjustment, or diagnostic checks for the primary time-to-event analysis.

The posted PFS comparison has a hazard ratio of 0.16, a 95% confidence interval from 0.09 to 0.28, and p < 0.001. The p-value addresses how compatible the observed test result is with a null comparison under the method's assumptions; it is not the probability that the null hypothesis is true. It does not measure clinical importance, and it does not quantify the probability that the result will replicate.

How should binary outcomes be read?

Overall response rate and sustained hemoglobin improvement are binary outcomes in the posted results: each participant is classified as meeting or not meeting the outcome definition. The registry reports outcome percentages by arm. For overall response, the values are 82.4% for ibrutinib and 35.3% for chlorambucil. For sustained hemoglobin improvement, they are 45.6% and 20.3%, respectively. These percentages describe the recorded groups; they do not by themselves account for uncertainty or for differences in analysis method.

The registry lists a Cochran-Mantel-Haenszel analysis for overall response and a Chi-squared analysis for sustained hemoglobin improvement. The recalculated unadjusted comparisons use the posted group summaries, while the sponsor's reported analyses use their listed methods. These are not automatically identical analyses. In general, a confidence interval for a binary contrast describes uncertainty around the estimated difference or ratio, while a p-value evaluates evidence against a null comparison under a specified test. The posted sponsor results for these secondary outcomes report p-values but not corresponding effect estimates or confidence intervals.

What does the intention-to-treat population mean?

In general, an intention-to-treat analysis retains participants in the groups to which they were randomized, regardless of later treatment changes, according to the analysis rules. This approach preserves the randomized comparison more directly than analyses that regroup participants by treatment received. The registry identifies intention to treat as the primary PFS population. It does not provide detailed participant flow, the number included in each specific analysis beyond the arm counts, or the handling of missing endpoint information. Thus, the population label is informative but does not resolve every question about analysis implementation.

Why do the reported and recalculated analyses differ in scope?

The recalculated binary comparisons are simple unadjusted calculations from the posted arm-level summaries. They can be useful as a transparent check on the scale and direction of a contrast, but they do not reproduce a stratified or otherwise adjusted sponsor analysis unless the needed details are available and the methods match. For PFS and overall survival, the time-to-event estimates used are the sponsor's reported hazard ratios; the posted summaries do not permit an independent reconstruction of participant-level event-time analyses. The registry record does not report participant-level data or full analysis specifications.

General statistical interpretation should distinguish an estimate, its confidence interval, and its test result. The estimate gives the direction and magnitude on a chosen scale; the interval communicates precision; and the p-value summarizes evidence against a null under a testing framework. None alone gives a complete account of design quality, missing data, outcome relevance, or generalizability.

11. Confidence Intervals and Precision

A 95% confidence interval expresses uncertainty around an estimated quantity under the analysis method. In general, it is a range generated by a procedure that would cover the true value in 95% of repeated applications under its assumptions. It is not a statement that there is a 95% probability that the particular interval contains the true value. The interval's width gives a sense of precision: narrower intervals generally indicate more precise estimates than wider ones, all else being equal.

For PFS, the registry reports a hazard ratio of 0.16 with a 95% confidence interval from 0.09 to 0.28. The interval is wholly on one side of 1, the value representing equal hazards. This is consistent with the reported p < 0.001 under the stated analysis. The interval nevertheless allows a range of relative hazard estimates, so the point estimate should not be treated as exact. The estimate is relative, and the interval does not convey absolute event probabilities at a particular time.

The chlorambucil median PFS is 18.9 months, with a 95% confidence interval from 14.1 to 22.0 months. The registry does not report the ibrutinib median or its interval. A confidence interval for one arm's median cannot be used alone to infer the precision of a difference between arms.

For overall survival, the registry reports a hazard ratio of 0.16 with a 95% confidence interval from 0.05 to 0.56 and p = 0.001. Both arm-specific medians are not reported in the registry record. For the binary outcomes, recalculated uncertainty is based on posted group summaries, while the sponsor-reported analyses use their stated methods and do not include an effect confidence interval in the registry record. Precision should therefore be interpreted in light of which estimate and analysis are being considered, rather than treating every displayed p-value as an equally informative measure of effect size.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning illustrations are based on the observed effect, not on the trial's original design justification. For time-to-event outcomes, the listed figures are total events, not participants per arm. For binary outcomes, the figures are participants per arm. The illustrations assume a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. The original trial's sample-size assumptions are not reported in the registry record.

The 80% power column means the illustrated design would have an 80% probability of detecting the specified effect under the planning assumptions if that effect were the true one. The 90% column expresses the same idea at a 90% probability. These are design-planning probabilities, not probabilities that the observed conclusion is correct. For the PFS planning illustration, using 100% of the observed effect corresponds to 10 total events for 80% power and 13 total events for 90% power. For overall response, the corresponding illustration is 16 participants per arm for 80% power and 21 participants per arm for 90% power.

Rows using 75% or 50% of the observed effect ask what would be needed to detect a smaller effect. Smaller effects are harder to distinguish from random variation, so the illustrations require more participants or events. For example, the PFS illustration at 50% of the observed effect lists 38 total events for 80% power and 51 for 90% power; the overall-response illustration lists 58 participants per arm and 77 participants per arm, respectively. These figures are not a reconstruction of the original design and are not observed power. They are planning illustrations based on the posted effect estimates and stated assumptions.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

d is the total number of events needed (Schoenfeld's formula) with 1:1 allocation and proportional hazards.

Worked calculation for this trial

1. Hazard ratio HR = 0.160, so ln(HR) = -1.8326.
2. d = 4 × (1.96 + 0.842)² / [ln(0.160)]² = 9.3, rounded up to 10 events in total for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
hr <- 0.16                              # observed hazard ratio
events_needed <- function(power, frac = 1) ceiling(round(4 * (z_a + qnorm(power))^2 / log(hr^frac)^2, 6))   # Schoenfeld, 1:1 allocation
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: events = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(events_needed(0.80, f), big.mark = ","), format(events_needed(0.90, f), big.mark = ",")))

# Simulation: given d total events under proportional hazards, events in the treatment arm are Binomial(d, hr / (1 + hr)).
# The score (log-rank type) statistic is (D1 - d / 2) / sqrt(d / 4).
set.seed(1722487)
d    <- events_needed(0.80)
reps <- 20000
D1 <- rbinom(reps, d, hr / (1 + hr))
z  <- (D1 - d / 2) / sqrt(d / 4)
cat(sprintf("Simulated power with %s events: %.3f (%d replicates)\n", format(d, big.mark = ","), mean(abs(z) > z_a), reps))

Output from running the code

100% of observed effect: events = 10 (80% power), 13 (90% power)
 75% of observed effect: events = 17 (80% power), 23 (90% power)
 50% of observed effect: events = 38 (80% power), 51 (90% power)
Simulated power with 10 events: 0.585 (20000 replicates)

The simulation uses the fact that, with d events in total and proportional hazards, the number of events in the treatment arm is binomial. It is an approximation that conditions on the total number of events, and it should land close to the target power.

14. Analyses Reported by the Sponsor

The sponsor-reported primary PFS analysis is a Log Rank comparison with a hazard ratio of 0.16, a 95% confidence interval from 0.09 to 0.28, and p < 0.001. The time-to-event hazard ratio used in the statistical presentation is the sponsor's reported estimate; the posted arm summaries do not permit an independent recalculation of a participant-level time-to-event result. The registry does not flag a discrepancy between the reported result and the statistical presentation.

For overall survival, the sponsor reports a hazard ratio of 0.16, a 95% confidence interval from 0.05 to 0.56, and p = 0.001. Its reported analyses for overall response and sustained hemoglobin improvement list Cochran-Mantel-Haenszel and Chi-squared methods, respectively. The registry gives sponsor p-values for these outcomes but no sponsor effect estimates or confidence intervals for those analyses.

Unadjusted recalculations from the posted binary summaries are a separate check, not a replacement for the sponsor's analyses. They may differ because the sponsor's method and the unadjusted calculation need not use the same adjustment or assumptions. If a discrepancy were recorded, the sponsor's own analysis would take precedence; no discrepancy is recorded for this trial. The exact adjusted effect estimates for the binary outcomes are not reported in the registry record.

15. Multiplicity, Missing Data and Analysis Populations

The registry identifies PFS as the primary outcome and lists six secondary outcomes, including overall survival, overall response, sustained hemoglobin improvement, and platelet-improvement outcomes. It does not report a complete prespecified statistical analysis plan, an outcome hierarchy, or a procedure for adjusting secondary tests for multiplicity. In general, testing many outcomes creates more opportunities for chance findings. Without a reported multiplicity strategy, secondary p-values should be interpreted cautiously and should not be given the same confirmatory weight as the designated primary analysis.

The registry record does not report whether interim analyses were planned or conducted, whether any stopping boundaries were used, or whether the reported analysis was selected from multiple looks at accumulating data. These details cannot be inferred from the primary completion date or the analysis cutoff.

The primary population is identified as intention to treat, but the registry does not describe missing-data handling, censoring rules, the amount of missing outcome information, or sensitivity analyses. These omissions matter because time-to-event analyses rely on follow-up and censoring information, while binary analyses depend on how participants without an observed outcome are classified or excluded. No assumptions about those procedures can be made from the arm-level results alone.

The registry also does not report detailed participant flow, protocol deviations, adherence, or the number of participants contributing to each endpoint beyond the posted arm counts. It gives a median follow-up time of 18 month but does not provide a distribution of follow-up. Without these details, it is not possible to assess fully how incomplete follow-up or analysis exclusions might affect the estimates. These are limits on interpretation of the registry record, not evidence that a particular bias occurred.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pyrexia (3.8%), pneumonia (3.7%), basal cell carcinoma (3.7%), hyponatraemia (2.2%), anaemia (1.5%).

The registry's serious adverse event summary lists 135 participants at risk in the PCI-32765 safety group, of whom 55 were affected, and 132 at risk in the chlorambucil group, of whom 33 were affected. For other adverse events, it lists 133 of 135 and 123 of 132 participants affected, respectively. These are counts of participants recorded as affected, not a comparison adjusted for exposure time or a complete description of event severity and duration.

The most frequent listed serious terms include pyrexia at 3.8%, pneumonia at 3.7%, basal cell carcinoma at 3.7%, hyponatraemia at 2.2%, anaemia at 1.5%, and febrile neutropenia at 1.5%. The registry record does not provide enough detail to determine whether participants could contribute to multiple terms or how events were adjudicated. Death counts are not reported in the registry record. These summaries describe reported adverse events and do not, on their own, establish causation or provide a complete benefit-harm assessment.

17. What the Result Does, and Does Not, Mean

The primary result is a statistically precise relative comparison under the reported Log Rank analysis: the posted PFS hazard ratio is 0.16, with a 95% confidence interval from 0.09 to 0.28 and p < 0.001. The result describes the recorded time-to-event comparison between the randomized groups in this trial. The confidence interval indicates that the point estimate is not exact, even though its reported range lies below 1.

This result does not provide an absolute risk difference at a particular time, and it does not say how many months of PFS separate the groups. The registry reports the chlorambucil median PFS as 18.9 months but does not report the ibrutinib median. It is therefore not possible to state an arm-to-arm median difference from the registry record. Nor does the hazard ratio state an individual participant's prognosis.

The trial's findings apply most directly to the enrolled population: treatment-naive patients aged 65 years or older with chronic lymphocytic leukemia or small lymphocytic lymphoma. They do not automatically generalize to other populations, disease settings, or treatment comparisons. The open-label design, the independent review committee for the primary assessment, and the registry's limited reporting of analysis details are all relevant context.

Secondary outcomes show additional numerical comparisons, but the registry does not report a multiplicity strategy, and some secondary results lack sponsor effect estimates or confidence intervals. They should not be read as equivalent to the prespecified primary endpoint. The safety summaries are also limited to recorded affected-participant counts and listed serious terms; they do not provide a full account of exposure, event attribution, or all potential harms.

Overall, the record supports a description of the observed trial results and their reported statistical uncertainty. It does not by itself establish how later evidence, longer follow-up, or different patient circumstances would affect the comparison. Statistical significance is not the same as clinical importance, and these results are not individualized medical advice.

18. Why This Trial Matters Statistically

This trial illustrates why a clinical study can need several distinct statistical summaries. PFS is a time-to-event outcome, so its analysis uses event timing and follow-up rather than only a count of participants with progression. The reported hazard ratio describes a relative event rate across follow-up, while the median describes an event-time landmark. The registry reports one arm's median but not the other's, making it especially important not to substitute the hazard ratio for an unavailable median contrast.

The trial also illustrates the distinction between a sponsor analysis and a simple recalculation from posted summaries. The primary hazard ratio comes from the sponsor's Log Rank analysis and cannot be reproduced independently from arm-level counts. For binary outcomes, unadjusted calculations can give a transparent comparison, but sponsor analyses may use different methods. Those estimates and p-values should not be treated as though they necessarily answer identical statistical questions.

Interpretation also depends on precision and the scope of reporting. A confidence interval gives more information about uncertainty than a p-value alone, while the absence of a reported interval for sponsor binary analyses limits direct assessment of their precision. The registry's lack of detail on multiplicity, missing data, interim analyses, and original sample-size assumptions further distinguishes a reported result from a complete statistical account.

Finally, safety and efficacy summaries answer different questions. Serious adverse event counts provide context about events recorded during the trial, but they are not a complete risk comparison. Reading endpoint definitions, analysis populations, follow-up, and reporting limits together is essential to a careful interpretation of clinical trial statistics.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific reporting limits affect interpretation. Although the study is described as open label and the primary outcome as independently assessed, the registry record does not describe the review committee's masking, operating procedures, or adjudication process. It also does not provide detailed participant flow, endpoint-specific missingness, censoring rules, protocol deviations, or sensitivity analyses.

The primary PFS result includes a reported hazard ratio and confidence interval, but the ibrutinib median PFS is not reported in the registry record. For overall survival, neither arm-specific median is reported. The analysis cutoff and median follow-up are stated, but the record does not give a follow-up distribution or later outcome updates. This limits description of absolute event timing and how results might change with additional follow-up.

The registry does not report the original sample-size justification, interim analysis plan, or a complete statistical analysis plan. It also does not describe adjustment for multiple secondary comparisons. Several listed secondary outcomes lack detailed numerical results in the record, and the sponsor's reported binary analyses do not include effect estimates and confidence intervals. Unadjusted calculations from posted summaries cannot fill these gaps or reproduce every sponsor method.

Safety reporting is similarly limited: the available summary gives affected-participant counts and selected serious adverse event terms, but deaths are not reported in the registry record, and the information does not describe exposure-adjusted rates or attribution. These limitations identify what the registry record does not establish; they do not demonstrate that a particular analysis or outcome was biased.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL — NCT01722487.
• Registry record last updated 2017-11-30; status last verified 2017-10.
• Results first posted 2016-05-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

The registry describes NCT01722487 as a completed randomized, multicenter, open-label, parallel-group Phase 3 study comparing ibrutinib with chlorambucil in treatment-naive patients aged 65 years or older with chronic lymphocytic leukemia or small lymphocytic lymphoma. Total enrollment was 269. The primary outcome was progression-free survival assessed by an independent review committee, with intention to treat listed as the analysis population.

The primary analysis reports a hazard ratio of 0.16, a 95% confidence interval from 0.09 to 0.28, and p < 0.001. The chlorambucil median PFS was 18.9 months; the ibrutinib median is not reported in the registry record. The record also includes overall survival, response, hemoglobin improvement, and safety results, with important limits in detail and analysis-plan reporting.